Safety And Efficacy clinical trials

Explore recruiting safety and efficacy clinical trials.

Recruiting safety and efficacy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Safety And Efficacy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

ARTEGENE - A Phase 1/2 Open Label non randomized Study, multicentric, single arm evaluating the Safety and Efficacy of Gene Therapy of the severe combined immunodeficiency (SCID) caused by mutations in the human DCLRE1C gene (Artemis) by transplantation of a single dose of autologous CD34+ cells transduced ex vivo with the G2ARTE lentiviral vector expressing the DCLRE1C cDNA

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU 285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

France, Netherlands, Denmark, Sweden, Germany, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention?

Netherlands, Belgium, Italy, Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Safety And Efficacy trials by city

Safety And Efficacy in Toronto Safety And Efficacy in Vancouver Safety And Efficacy in Montreal Safety And Efficacy in Calgary Safety And Efficacy in Edmonton Safety And Efficacy in Ottawa Safety And Efficacy in Winnipeg Safety And Efficacy in Quebec City Safety And Efficacy in Hamilton Safety And Efficacy in Kitchener Safety And Efficacy in London Safety And Efficacy in Halifax Safety And Efficacy in New York Safety And Efficacy in Los Angeles Safety And Efficacy in Chicago Safety And Efficacy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease